Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods
暂无分享,去创建一个
Richard D. Smith | S. Srivastava | D. Camp | W. Qian | Tao Liu | K. Rodland | S. Srivastava | Tujin Shi | Yuqian Gao | Chaochao Wu | G. Petrovics | A. Srinivasan | D. Mcleod | J. Kagan | A. Dobi | Shyh-Han Tan | Wei Huang | Jintang He | A. Schepmoes | A. Mohamed | Wusheng Yan | A. Rastogi | Sreedatta Banerjee | T. Fillmore
[1] S. Srivastava,et al. Predominance of ERG-negative high-grade prostate cancers in African American men. , 2014, Molecular and clinical oncology.
[2] M. Rubin,et al. Antibody‐independent targeted quantification of TMPRSS2‐ERG fusion protein products in prostate cancer , 2014, Molecular oncology.
[3] S. Srivastava,et al. ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity. , 2014, Monoclonal antibodies in immunodiagnosis and immunotherapy.
[4] T. D. de Reijke,et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. , 2014, European urology.
[5] Ronald J. Moore,et al. Targeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletion. , 2013, Journal of proteome research.
[6] S. Srivastava,et al. Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India , 2013, Journal of Cancer.
[7] C. Cooper,et al. The Present and Future of Prostate Cancer Urine Biomarkers , 2013, International journal of molecular sciences.
[8] A. Uren,et al. Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer. , 2013, American journal of translational research.
[9] L. Cartegni,et al. 5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer , 2013, PloS one.
[10] W. Qian,et al. Antibody-free PRISM-SRM for multiplexed protein quantification: is this the new competition for immunoassays in bioanalysis? , 2013, Bioanalysis.
[11] S. Srivastava,et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. , 2012, Urology.
[12] Ronald J. Moore,et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum , 2012, Proceedings of the National Academy of Sciences.
[13] R. Aebersold,et al. Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions , 2012, Nature Methods.
[14] Richard D. Smith,et al. Advancing the sensitivity of selected reaction monitoring‐based targeted quantitative proteomics , 2012, Proteomics.
[15] John T. Wei,et al. Beyond PSA: The Next Generation of Prostate Cancer Biomarkers , 2012, Science Translational Medicine.
[16] G. Kristiansen,et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer—a comparative study of two monoclonal antibodies , 2012, Prostate Cancer and Prostatic Diseases.
[17] Arul M Chinnaiyan,et al. Common gene rearrangements in prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] S. Varambally,et al. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. , 2011, Cancer research.
[19] Nallasivam Palanisamy,et al. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.
[20] L. Waldron,et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes , 2011, BMC biotechnology.
[21] M. Rubin,et al. TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients , 2011, The Prostate.
[22] S. Varambally,et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.
[23] D. Berney,et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. , 2010, Cancer research.
[24] S-H Tan,et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification , 2010, Prostate Cancer and Prostatic Diseases.
[25] Brendan MacLean,et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments , 2010, Bioinform..
[26] S. Booth,et al. Quantitative Reverse-Transcription Polymerase Chain Reaction Analysis of Alzheimer's-Associated Genes in Mouse Scrapie , 2009, Journal of toxicology and environmental health. Part A.
[27] R. Aebersold,et al. Selected reaction monitoring for quantitative proteomics: a tutorial , 2008, Molecular systems biology.
[28] Jennifer L. Osborn,et al. Direct multiplexed measurement of gene expression with color-coded probe pairs , 2008, Nature Biotechnology.
[29] A. Chinnaiyan,et al. Recurrent gene fusions in prostate cancer , 2008, Nature Reviews Cancer.
[30] R. Eeles,et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.
[31] V. Srikantan,et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2006, Oncogene.
[32] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[33] V. Srikantan,et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.
[34] D. Albertson,et al. Chromosome aberrations in solid tumors , 2003, Nature Genetics.
[35] J. Cheville,et al. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.
[36] Matthias Kretzler,et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. , 2002, The American journal of pathology.
[37] L. Hood,et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.
[38] V. Sementchenko,et al. ETS2 function is required to maintain the transformed state of human prostate cancer cells , 1998, Oncogene.
[39] T. Papas,et al. The erg gene: a human gene related to the ets oncogene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[40] T. Papas,et al. erg, a human ets-related gene on chromosome 21: alternative splicing, polyadenylation, and translation. , 1987, Science.